Thomas...'s questions to Myriad Genetics Inc (MYGN) leadership • Q4 2024
Question
Thomas..., on behalf of Subbu Nambi, asked about the company's focus for Prolaris amid NCCN guideline confusion and the strategy for GeneSight following recent payer decisions, specifically regarding where management is focusing its efforts.
Answer
Chief Commercial Officer Mark Verratti explained that for Prolaris, the focus is on KOL engagement to clear up guideline confusion and increased investment, bolstered by the new PATHOMIQ AI partnership. For GeneSight, he clarified that the sales force remains focused on providers, while the executive team separately handles payer engagement, evidence generation, and advocacy. CEO Paul Diaz added that state biomarker legislation is a key initiative to mitigate the UnitedHealthcare policy change.